… Cumberbatch e , Maria De Santis f g , Stefano Fanti h , Nicola Fossati i j , Giorgio Gandaglia
i j , Silke Gillessen k l m , Nikos Grivas n , Jeremy … Oprea-Lager x … Philip Cornford gg …

… The majority of patients treated had de novo metastatic disease, and the evidence is most
compelling in this situation. However, it may still be considered for men progressing after local …

Context There is uncertainty regarding the most appropriate criteria for recruitment, monitoring,
and reclassification in active surveillance (AS) protocols for localised prostate cancer (…

… Furthermore, aggressive forms of primary neuroendocrine PCa or neuroendocrine de-differentiation
after AR-targeted therapies in metastatic CRPC (mCRPC) might show a reduced …

… , BlueEarth Diagnostics, Janssen Cilag ROTOP, Phillips, and grants from Acelity, outside
the submitted work; Steven MacLennan reports no conflicts of interest; Daniela Oprea-Lager …

Purpose Quantitative prostate-specific membrane antigen (PSMA) PET analysis may provide
for non-invasive and objective risk stratification of primary prostate cancer (PCa) patients. …

Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …

The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for
selecting non–small cell lung cancer (NSCLC) patients for single-agent treatment with …

Better biomarkers are needed to predict treatment outcome in non–small cell lung cancer (NSCLC)
patients treated with anti–programmed death-1/programmed death-ligand 1 (PD-1/…

Purpose The detection of lymph-node metastases (N1) with conventional imaging such as
magnetic resonance imaging (MRI) and computed tomography (CT) is inadequate for …